Top

Published in:

Open Access 01-08-2021 | Prostate Cancer | Original Research

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

Published in: Advances in Therapy | Issue 8/2021

Abstract

Introduction

Therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) patients are continuously advancing. We described mCRPC treatment patterns in the US from 2013 to 2019.

Methods

Patients with a confirmed mCRPC diagnosis and adenocarcinoma histology were included in the US Flatiron Health Electronic Health Record-derived de-identified database. Treatment patterns [including treatment per lines of therapies (LOTs), LOT sequences, and time on treatment] and overall survival (OS) have been described in mCRPC settings.

Results

Of 5213 patients (mean age: 72.6 years), 4374 (83.9%) were treated with ≥ 1 LOT post-mCRPC diagnosis (among those with ≥ 1 LOT, 55.3%, 29.5%, 14.7%, and 6.7% had ≥ 2, 3, 4, and 5 LOTs, respectively). In first line (1L), the main treatment class was next-generation hormonal agents (NHA; 62.5% of patients with ≥ 1 LOT), while the shortest and longest time on 1L were observed for chemotherapy (median 2.8 months) and NHA (median 5.1 months), respectively. The most common LOT sequences were NHA → NHA (29.4% of patients with ≥ 2 LOTs) and NHA → NHA → chemotherapy (16.7% of patients with ≥ 3 LOTs). In Kaplan–Meier analyses, the median OS was 19.4, 14.6, and 11.1 months post-1L, 2L, and 3L start, respectively. Patients who moved rapidly through LOTs had an increased risk of death.

Conclusions

NHA were widely used as 1L therapy in mCRPC patients from 2013 to 2019, but time on 1L NHA treatment was on average < 6 months. While NHA → NHA was the most observed 1L → 2L LOT sequence, a plethora of other LOT sequences were observed. OS was poor, highlighting an unmet need for life-prolonging treatments.

Available only for authorised users

https://seer.cancer.gov/statfacts/html/prost.html. Accessed Sep 24, 2020.

Centers for disease control and prevention: prostate cancer statistics. 2020. https://www.cdc.gov/cancer/prostate/statistics/index.htm. Accessed Jul 13, 2020.

Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72–9. https://doi.org/10.3747/co.v17i0.718.CrossRefPubMedPubMedCentral

Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92. https://doi.org/10.1111/j.1742-1241.2011.02799.xCrossRefPubMed

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer. 2017;15(1):60–6. https://doi.org/10.1016/j.clgc.2016.08.018 (e2).CrossRefPubMed

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, et al. DNA repair in prostate cancer: biology and clinical implications. Eur Urol. 2017;71(3):417–25. https://doi.org/10.1016/j.eururo.2016.08.037.CrossRefPubMed

Corfield J, Crozier J, Joshua AM, Bolton D, Lawrentschuk N. Understanding the role of new systemic agents in the treatment of prostate cancer. BJU Int. 2016;118(Suppl 3):8–13. https://doi.org/10.1111/bju.13633.CrossRefPubMed

Wade CA, Kyprianou N. Profiling prostate cancer therapeutic resistance. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19030904.CrossRefPubMedPubMedCentral

Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, et al. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38(1):1e-e10. https://doi.org/10.1016/j.urolonc.2019.09.027.CrossRef

10.

George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovsky J, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020. https://doi.org/10.1016/j.clgc.2019.12.019.CrossRefPubMed

11.

Higano CS, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, et al. Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. Am Soc Clin Oncol. 2019;37(7_suppl):256.CrossRef

12.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–102. https://doi.org/10.1056/NEJMoa1911440.CrossRefPubMed

13.

United States Food and Drug Administration: RUBRACA® (rucaparib)—accelerated approval. 2020,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209115Orig1s004ltr.pdf. Accessed Jun 24, 2020.

14.

United States Food and Drug Administration: FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. 2020. https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate. Accessed Sep 25, 2020.

15.

Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38(32):3763.CrossRefPubMedPubMedCentral

16.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed [June 24, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed.

17.

Moses KA, Wallace K, Landsteiner A, Bunner S, Engel-Nitz N, Lal LS, et al. Real-world evidence of treatment patterns and pharmacy costs among patients with metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.2020.38.15_suppl.e19319.CrossRef

18.

Wen L, Yao J, Valderrama A. Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. J Manag Care Spec Pharm. 2019;25(3-b Suppl):S1–11. https://doi.org/10.18553/jmcp.2019.25.3-b.s1.CrossRefPubMed

19.

Sonpavde G, Huang A, Wang L, Baser O, Miao R. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. BJU Int. 2018;121(6):871–9. https://doi.org/10.1111/bju.14152.CrossRefPubMed

20.

George DJ, Sternberg CN, Sartor AO, Saad F, Tombal BF, Miller K, et al. Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Am Soc Clin Oncol. 2019;37(7_suppl):253.CrossRef

21.

Flatiron Health Database. 2020. https://flatiron.com/real-world-evidence/. Accessed Jun 18, 2020.

22.

Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medrRxiv. 2020;105:912.

23.

Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS ONE. 2015;10(10): e0139440. https://doi.org/10.1371/journal.pone.0139440.CrossRefPubMedPubMedCentral

24.

Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55(3):323–7. https://doi.org/10.1016/s0090-4295(99)00471-9.CrossRefPubMed

25.

Lam J, Yang C, Kaiser C, Wong W. Real-world treatment patterns and care pathways in metastatic castration resistant prostate cancer. Value Health. 2018;21:S41.CrossRef

26.

Curtis MD, Griffith SD, Tucker M, Taylor MD, Capra WB, Carrigan G, et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res. 2018;53(6):4460–76. https://doi.org/10.1111/1475-6773.12872.CrossRefPubMedPubMedCentral

27.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 3.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed [June 24, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed.

28.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed [Jun 24, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed.

29.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 4.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed [Jun 24, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed.

30.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed [Jun 24, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed.

31.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed [Feb 18, 2021]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.: Accessed.

32.

Janssen Pharmaceutical Companies: ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer. 2018. https://www.prnewswire.com/news-releases/zytiga-abiraterone-acetate-plus-prednisone-approved-for-treatment-of-earlier-form-of-metastatic-prostate-cancer-300595759.html. Accessed Jun 24, 2020.

33.

XTANDI® (enzalutamide) Capsules, for Oral Use [Prescribing Information]: United States Food and Drug Administration; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203415s015lbl.pdf. Accessed Jun, 24 2020.

34.

ZYTIGA® (abiraterone acetate) Tablets, for Oral Use [Prescribing Information]: United States Food and Drug Administration; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202379s031s033lbl.pdf. Accessed Jun, 24 2020.

35.

ERLEADA® (apalutamide) Tablets [Prescribing Information]: United States Food and Drug Administration; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf. Accessed Jun 24, 2020.

36.

Lorente D, Fizazi K, Sweeney C, de Bono JS. Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus. 2016;2(5):488–98. https://doi.org/10.1016/j.euf.2016.10.008.CrossRefPubMed

37.

Wallis CJD, Klaassen Z. What is changing in advanced prostate cancer? Everyday Urol. 2021;5(2).

38.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer–Version 2.2014. © National Comprehensive Cancer Network, Inc. 2014. All rights reserved. Accessed [Jun, 24, 2020]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed.

39.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. https://doi.org/10.1016/S1470-2045(14)71205-7.CrossRefPubMed

40.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. https://doi.org/10.1056/NEJMoa1207506.CrossRefPubMed

41.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRefPubMedPubMedCentral

42.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. https://doi.org/10.1056/NEJMoa1405095.CrossRefPubMedPubMedCentral

43.

Roberts MH, Ferguson GT. Real-world evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon Open. 2021;5(1):3–11. https://doi.org/10.1007/s41669-020-00221-y.CrossRefPubMed

44.

Blumenthal DM, Yu-Isenberg K, Yee J, Jena AB. Real-world evidence complements randomized controlled trials in clinical decision making. Health Affairs Blog. 2017.

45.

Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, et al. Results of the FLAC European database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor-targeted agents. Clin Genitourin Cancer. 2018;16(4):e777–84. https://doi.org/10.1016/j.clgc.2018.02.016.CrossRefPubMed

46.

Maines F, Caffo O, Veccia A, Trentin C, Tortora G, Galligioni E, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96(3):498–506. https://doi.org/10.1016/j.critrevonc.2015.07.013.CrossRefPubMed

47.

Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015;13(4):309–18. https://doi.org/10.1016/j.clgc.2014.12.019.CrossRefPubMed

48.

Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen FB, Schmid S, et al. Survival outcomes from a cumulative analysis of worldwide observational studies on sequential use of new agents in metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2020;18(1):69–76. https://doi.org/10.1016/j.clgc.2019.09.010 (e4).CrossRefPubMed

49.

Caffo O, Bria E, Giorgi UD, Tucci M, Galli L, Fratino L, et al. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: final analysis from a multicenter Italian study. J Clin Oncol. 2017;35(15_suppl):5030. https://doi.org/10.1200/JCO.2017.35.15_suppl.5030.CrossRef

50.

Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, et al. Investigating BRCA mutations: a breakthrough in precision medicine of castration-resistant prostate cancer. Target Oncol. 2016;11(5):569–77. https://doi.org/10.1007/s11523-016-0450-9.CrossRefPubMed

51.

Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019;16(11):645–54. https://doi.org/10.1038/s41585-019-0237-8.CrossRefPubMedPubMedCentral

52.

Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara P, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. Am Soc Clin Oncol. 2019;30:v884–5.

53.

RUBRACA® (rucaparib) Tablets, for Oral Use [Prescribing Information]: United States Food and Drug Administration; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf Accessed Jun 24, 2020.

Title: Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Publication date: 01-08-2021
Keywords: Prostate Cancer
Prostate Cancer
Cytostatic Therapy
Enzalutamide
Published in: Advances in Therapy / Issue 8/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-021-01823-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

Abstract

Introduction

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2021

Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study

Electromyographic Biofeedback for Stress Urinary Incontinence or Pelvic Floor Dysfunction in Women: A Systematic Review and Meta-Analysis

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan

Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis

Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review

Correction to: Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page